Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging
Sponsor: National Cancer Institute (NCI)
Listed as NCT01446809, this NA trial focuses on Stage IIA Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
May 2020 — Jan 2021 [monthly]
Completed NA
-
Jul 2019 — May 2020 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Dec 2018 — May 2019 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .